Global Genomics Group (G3) and Caprion to Partner on GLOBAL Study to Identify Cardiovascular Disease Biomarkers and Drug Targets
February 26, 2014
RICHMOND, Va. and MONTREAL, Feb. 26, 2014 /PRNewswire/ — Global Genomics Group (G3) and Caprion Proteomics, Inc., today announced that they have entered into a collaboration agreement to investi...
G3, Quintiles Enter Target Discovery Alliance
February 19, 2014
Global Genomics Group (G3) and Quintiles have entered a collaboration to investigate novel biomarkers and biological pathways for use in the development of diagnostic tools and treatments for cardiova...
Global Genomics Group (G3) Completes Patient Enrollment of Discovery Cohort in GLOBAL Study Ahead of Schedule
February 13, 2014
RICHMOND, Va., Feb. 13, 2014 /PRNewswire/ — Global Genomics Group (G3) today announced that it has completed enrollment of the 5,000-patient discovery cohort of its GLOBAL (Genetic LOci and Burd...
Interview with Dr. Szilard Voros, CEO and Co-Founder of Global Genomics Group
February 27, 2014
Dr. Szilard Voros, CEO and co-founder of Global Genomics Group (G3), is currently heading the international GLOBAL study, which will enroll up to 10,000 patients with coronary artery disease. The coro...